Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Hansten, PD; Levy, RH
   Role of P-glycoprotein and organic anion transporting polypeptides in drugabsorption and distribution - Focus on H-1-receptor antagonists
   CLINICAL DRUG INVESTIGATION
   
   P.D. Hansten e R.H. Levy, "Role of P-glycoprotein and organic anion transporting polypeptides in drugabsorption and distribution - Focus on H-1-receptor antagonists", CLIN DRUG I, 21(8), 2001, pp. 587-596
2. Ragueneau-Majlessi, I; Levy, RH; Meyerhoff, C
   Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin
   EPILEPSY RESEARCH
   
   I. Ragueneau-Majlessi et al., "Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin", EPILEPSY R, 47(1-2), 2001, pp. 55-63
3. Levy, RH; Ragueneau-Majlessi, I; Baltes, E
   Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers
   EPILEPSY RESEARCH
   
   R.H. Levy et al., "Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers", EPILEPSY R, 46(2), 2001, pp. 93-99
4. Bialer, M; Johannessen, SI; Kupferberg, HJ; Levy, RH; Loiseau, P; Perucca, E
   Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
   EPILEPSY RESEARCH
   
   M. Bialer et al., "Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)", EPILEPSY R, 43(1), 2001, pp. 11-58
5. Yao, CP; Kunze, KL; Kharasch, ED; Wang, Y; Trager, WF; Ragueneau, I; Levy, RH
   Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2
   CLINICAL PHARMACOLOGY & THERAPEUTICS
   
   C.P. Yao et al., "Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2", CLIN PHARM, 70(5), 2001, pp. 415-424
6. Mather, GG; Labroo, R; Le Guern, ME; Lepage, F; Gillardin, JM; Levy, RH
   Nefopam enantiomers: Preclinical pharmacology/toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration
   CHIRALITY
   
   G.G. Mather et al., "Nefopam enantiomers: Preclinical pharmacology/toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration", CHIRALITY, 12(3), 2000, pp. 153-159
7. Wang, XY; Levy, RH; Ho, RJY
   Development of a semi-quantitative assay to detect full-length CYP2C19 RNA
   BIOTECHNIQUES
   
   X.Y. Wang et al., "Development of a semi-quantitative assay to detect full-length CYP2C19 RNA", BIOTECHNIQU, 29(2), 2000, pp. 364
8. Spiegelstein, O; Kroetz, DL; Levy, RH; Yagen, B; Hurst, SI; Levi, M; Haj-Yehia, A; Bialer, M
   Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid
   PHARMACEUTICAL RESEARCH
   
   O. Spiegelstein et al., "Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid", PHARM RES, 17(2), 2000, pp. 216-221
9. Levy, RH
   Reply to David Wyman (Bombing of Auschwitz)
   HOLOCAUST AND GENOCIDE STUDIES
   
   R.H. Levy, "Reply to David Wyman (Bombing of Auschwitz)", HOLOC GENOC, 13(3), 1999, pp. 536-536
10. Rettie, AE; Haining, RL; Bajpai, M; Levy, RH
    A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin
    EPILEPSY RESEARCH
    
    A.E. Rettie et al., "A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin", EPILEPSY R, 35(3), 1999, pp. 253-255
11. Bialer, M; Johannessen, SI; Kupferberg, HJ; Levy, RH; Loiseau, P; Perucca, E
    Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
    EPILEPSY RESEARCH
    
    M. Bialer et al., "Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)", EPILEPSY R, 34(1), 1999, pp. 1-41
12. Finnell, RH; Bennett, GD; Mather, GG; Wlodarczyk, B; Bajpai, M; Levy, RH
    Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model
    REPRODUCTIVE TOXICOLOGY
    
    R.H. Finnell et al., "Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model", REPROD TOX, 13(2), 1999, pp. 85-91
13. Spiegelstein, O; Yagen, B; Levy, RH; Finnell, RH; Bennett, GD; Roeder, M; Schurig, V; Bialer, M
    Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid
    PHARMACEUTICAL RESEARCH
    
    O. Spiegelstein et al., "Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid", PHARM RES, 16(10), 1999, pp. 1582-1588
14. Erickson, DA; Mather, G; Trager, WF; Levy, RH; Keirns, JJ
    Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450
    DRUG METABOLISM AND DISPOSITION
    
    D.A. Erickson et al., "Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450", DRUG META D, 27(12), 1999, pp. 1488-1495
15. Shen, DD; Levy, RH
    Valproate
    ANTIEPILEPTIC DRUGS
    
    D.D. Shen e R.H. Levy, "Valproate", HANDB EXP P, 138, 1999, pp. 359-373
16. Yao, CP; Mather, GG; Stephens, JR; Levy, RH
    Cytotoxicity induced by the combination of valproic acid and tumor necrosis factor-alpha - Implication for valproic acid-associated hepatotoxicity syndrome
    BIOCHEMICAL PHARMACOLOGY
    
    C.P. Yao et al., "Cytotoxicity induced by the combination of valproic acid and tumor necrosis factor-alpha - Implication for valproic acid-associated hepatotoxicity syndrome", BIOCH PHARM, 58(3), 1999, pp. 455-459
17. BIALER M; LEVY RH; PERUCCA E
    DOES CARBAMAZEPINE HAVE A NARROW THERAPEUTIC PLASMA-CONCENTRATION RANGE
    Therapeutic drug monitoring
    
    M. Bialer et al., "DOES CARBAMAZEPINE HAVE A NARROW THERAPEUTIC PLASMA-CONCENTRATION RANGE", Therapeutic drug monitoring, 20(1), 1998, pp. 56-59
18. Wilson, GS; Harwood, DM; Askin, RA; Levy, RH
    Late Neogene Sirius Group strata in Reedy Valley, Antarctica: a multiple-resolution record of climate, ice-sheet and sea-level events
    JOURNAL OF GLACIOLOGY
    
    G.S. Wilson et al., "Late Neogene Sirius Group strata in Reedy Valley, Antarctica: a multiple-resolution record of climate, ice-sheet and sea-level events", J GLACIOL, 44(148), 1998, pp. 437-447
19. BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
    CONFERENCE REPORT - PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT-CONFERENCE (VOL 25, PG 299, 1996)
    Epilepsy research
    
    M. Bialer et al., "CONFERENCE REPORT - PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT-CONFERENCE (VOL 25, PG 299, 1996)", Epilepsy research, 26(3), 1997, pp. 465-465
20. GLUE P; BANFIELD CR; PERHACH JL; MATHER GG; RACHA JK; LEVY RH
    PHARMACOKINETIC INTERACTIONS WITH FELBAMATE - IN-VITRO IN-VIVO CORRELATION
    Clinical pharmacokinetics
    
    P. Glue et al., "PHARMACOKINETIC INTERACTIONS WITH FELBAMATE - IN-VITRO IN-VIVO CORRELATION", Clinical pharmacokinetics, 33(3), 1997, pp. 214-224
21. HETTINGER ME; GILL DJ; ROBIN JB; LEVY RH; KOESTER J
    EVALUATION OF DICLOFENAC SODIUM 0.1-PERCENT OPHTHALMIC SOLUTION IN THE TREATMENT OF OCULAR SYMPTOMS AFTER BILATERAL RADIAL KERATOTOMY
    Cornea
    
    M.E. Hettinger et al., "EVALUATION OF DICLOFENAC SODIUM 0.1-PERCENT OPHTHALMIC SOLUTION IN THE TREATMENT OF OCULAR SYMPTOMS AFTER BILATERAL RADIAL KERATOTOMY", Cornea, 16(4), 1997, pp. 406-413
22. LEVY RH
    A NEW PERSPECTIVE ON THE ESSAY, THE BOMBING OF AUSCHWITZ, A CRITICAL ANALYSIS
    American Jewish history
    
    R.H. Levy, "A NEW PERSPECTIVE ON THE ESSAY, THE BOMBING OF AUSCHWITZ, A CRITICAL ANALYSIS", American Jewish history, 85(1), 1997, pp. 101-102
23. MORGANROTH J; LYNESS WH; PERHACH JL; MATHER GG; HARR JE; TRAGER WF; LEVY RH; ROSENBERG A
    LACK OF EFFECT OF AZELASTINE AND KETOCONAZOLE COADMINISTRATION ON ELECTROCARDIOGRAPHIC PARAMETERS IN HEALTHY-VOLUNTEERS
    Journal of clinical pharmacology
    
    J. Morganroth et al., "LACK OF EFFECT OF AZELASTINE AND KETOCONAZOLE COADMINISTRATION ON ELECTROCARDIOGRAPHIC PARAMETERS IN HEALTHY-VOLUNTEERS", Journal of clinical pharmacology, 37(11), 1997, pp. 1065-1072
24. MARTIN SW; BISHOP FE; KERR BM; MOOR M; MOORE M; SHEFFELS P; RASHED M; SLATTER JG; BERTHONCEDILLE L; LEPAGE F; DESCOMBE JJ; PICARD M; BAILLIE TA; LEVY RH
    PHARMACOKINETICS AND METABOLISM OF THE NOVEL ANTICONVULSANT AGENT ,6-DIMETHYLPHENYL)-5-METHYL-3-ISOXAZOLECARBOXAMIDE (D2624) IN RATS AND HUMANS
    Drug metabolism and disposition
    
    S.W. Martin et al., "PHARMACOKINETICS AND METABOLISM OF THE NOVEL ANTICONVULSANT AGENT ,6-DIMETHYLPHENYL)-5-METHYL-3-ISOXAZOLECARBOXAMIDE (D2624) IN RATS AND HUMANS", Drug metabolism and disposition, 25(1), 1997, pp. 40-46
25. STILWELL JD; LEVY RH; FELDMANN RM; HARWOOD DM
    ON THE RARE OCCURRENCE OF EOCENE CALLIANASSID DECAPODS (ARTHROPODA) PRESERVED IN THEIR BURROWS, MOUNT-DISCOVERY, EAST ANTARCTICA
    Journal of paleontology
    
    J.D. Stilwell et al., "ON THE RARE OCCURRENCE OF EOCENE CALLIANASSID DECAPODS (ARTHROPODA) PRESERVED IN THEIR BURROWS, MOUNT-DISCOVERY, EAST ANTARCTICA", Journal of paleontology, 71(2), 1997, pp. 284-287
26. ROSENFELD WE; LIAO S; KRAMER LD; ANDERSON G; PALMER M; LEVY RH; NAYAK RK
    COMPARISON OF THE STEADY-STATE PHARMACOKINETICS OF TOPIRAMATE AND VALPROATE IN PATIENTS WITH EPILEPSY DURING MONOTHERAPY AND CONCOMITANT THERAPY
    Epilepsia
    
    W.E. Rosenfeld et al., "COMPARISON OF THE STEADY-STATE PHARMACOKINETICS OF TOPIRAMATE AND VALPROATE IN PATIENTS WITH EPILEPSY DURING MONOTHERAPY AND CONCOMITANT THERAPY", Epilepsia, 38(3), 1997, pp. 324-333
27. TRAN A; REY E; PONS G; ROUSSEAU M; DATHIS P; OLIVE G; MATHER GG; BISHOP FE; WURDEN CJ; LABROO R; TRAGER WF; KUNZE KL; THUMMEL KE; VINCENT JC; GILLARDIN JM; LEPAGE F; LEVY RH
    INFLUENCE OF STIRIPENTOL ON CYTOCHROME P450-MEDIATED METABOLIC PATHWAYS IN HUMANS - IN-VITRO AND IN-VIVO COMPARISON AND CALCULATION OF IN-VIVO INHIBITION CONSTANTS
    Clinical pharmacology and therapeutics
    
    A. Tran et al., "INFLUENCE OF STIRIPENTOL ON CYTOCHROME P450-MEDIATED METABOLIC PATHWAYS IN HUMANS - IN-VITRO AND IN-VIVO COMPARISON AND CALCULATION OF IN-VIVO INHIBITION CONSTANTS", Clinical pharmacology and therapeutics, 62(5), 1997, pp. 490-504
28. MATHER GG; HARR JH; HARGREAVES JA; TRAGER WF; LEVY RH
    LACK OF HUMAN CYP450 INHIBITION BY TIZANIDINE AND 2 MAJOR METABOLITES
    Clinical pharmacology and therapeutics
    
    G.G. Mather et al., "LACK OF HUMAN CYP450 INHIBITION BY TIZANIDINE AND 2 MAJOR METABOLITES", Clinical pharmacology and therapeutics, 61(2), 1997, pp. 9-9
29. LEVY RH
    THE BOMBING OF AUSCHWITZ REVISITED - A CRITICAL ANALYSIS
    Holocaust and genocide studies
    
    R.H. Levy, "THE BOMBING OF AUSCHWITZ REVISITED - A CRITICAL ANALYSIS", Holocaust and genocide studies, 10(3), 1996, pp. 267-298
30. BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
    PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE
    Epilepsy research
    
    M. Bialer et al., "PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE", Epilepsy research, 25(3), 1996, pp. 299-319
31. LEVY RH
    SEDATION IN ACUTE AND CHRONIC AGITATION
    Pharmacotherapy
    
    R.H. Levy, "SEDATION IN ACUTE AND CHRONIC AGITATION", Pharmacotherapy, 16(6), 1996, pp. 152-159
32. MILLER DD; LEVY RH; RALEIGH F; LITTRELL RA; STIMMEL GL
    PANEL DISCUSSION
    Pharmacotherapy
    
    D.D. Miller et al., "PANEL DISCUSSION", Pharmacotherapy, 16(6), 1996, pp. 166-168
33. BAJPAI M; ROSKOS LK; SHEN DD; LEVY RH
    ROLES OF CYTOCHROME P4502C9 AND CYTOCHROME P4502C19 IN THE STEREOSELECTIVE METABOLISM OF PHENYTOIN TO ITS MAJOR METABOLITE
    Drug metabolism and disposition
    
    M. Bajpai et al., "ROLES OF CYTOCHROME P4502C9 AND CYTOCHROME P4502C19 IN THE STEREOSELECTIVE METABOLISM OF PHENYTOIN TO ITS MAJOR METABOLITE", Drug metabolism and disposition, 24(12), 1996, pp. 1401-1403
34. ANDERSON GD; YAU MK; GIDAL BE; HARRIS SJ; LEVY RH; LAI AA; WOLF KB; WARGIN WA; DREN AT
    BIDIRECTIONAL INTERACTION OF VALPROATE AND LAMOTRIGINE IN HEALTHY-SUBJECTS
    Clinical pharmacology and therapeutics
    
    G.D. Anderson et al., "BIDIRECTIONAL INTERACTION OF VALPROATE AND LAMOTRIGINE IN HEALTHY-SUBJECTS", Clinical pharmacology and therapeutics, 60(2), 1996, pp. 145-156
35. MARTIN SW; ELMER GW; VEGA R; MCFARLAND LV; LEVY RH
    PHARMACOKINETICS OF SACCHAROMYCES-BOULARDII WITHIN THE GASTROINTESTINAL-TRACT LUMEN
    Clinical pharmacology and therapeutics
    
    S.W. Martin et al., "PHARMACOKINETICS OF SACCHAROMYCES-BOULARDII WITHIN THE GASTROINTESTINAL-TRACT LUMEN", Clinical pharmacology and therapeutics, 59(2), 1996, pp. 88-88
36. STABLES JP; BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E
    PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE
    Epilepsy research
    
    J.P. Stables et al., "PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS A SUMMARY OF THE 2ND EILAT-CONFERENCE", Epilepsy research, 22(3), 1995, pp. 235-246
37. FINNELL RH; BENNETT GD; SLATTERY JT; AMORE BM; BAJPAI M; LEVY RH
    EFFECT OF TREATMENT WITH PHENOBARBITAL AND STIRIPENTOL ON CARBAMAZEPINE-INDUCED TERATOGENICITY AND REACTIVE METABOLITE FORMATION
    Teratology
    
    R.H. Finnell et al., "EFFECT OF TREATMENT WITH PHENOBARBITAL AND STIRIPENTOL ON CARBAMAZEPINE-INDUCED TERATOGENICITY AND REACTIVE METABOLITE FORMATION", Teratology, 52(6), 1995, pp. 324-332
38. LEVY RH
    RECENT ADVANCES IN ANTIEPILEPTIC DRUG PHARMACOKINETICS - A SYMPOSIUM - PREFACE
    Epilepsia
    
    R.H. Levy, "RECENT ADVANCES IN ANTIEPILEPTIC DRUG PHARMACOKINETICS - A SYMPOSIUM - PREFACE", Epilepsia, 36, 1995, pp. 5-5
39. LEVY RH
    CYTOCHROME-P450 ISOZYMES AND ANTIEPILEPTIC DRUG-INTERACTIONS
    Epilepsia
    
    R.H. Levy, "CYTOCHROME-P450 ISOZYMES AND ANTIEPILEPTIC DRUG-INTERACTIONS", Epilepsia, 36, 1995, pp. 8-13
40. LEVY RH; BISHOP F; STREETER AJ; TRAGER WF; KUNZE KL; THUMMEL KT; MATHER GG
    EXPLANATION AND PREDICTION OF DRUG-INTERACTIONS WITH TOPIRAMATE USINGA CYP450 INHIBITION SPECTRUM
    Epilepsia
    
    R.H. Levy et al., "EXPLANATION AND PREDICTION OF DRUG-INTERACTIONS WITH TOPIRAMATE USINGA CYP450 INHIBITION SPECTRUM", Epilepsia, 36, 1995, pp. 252-252
41. MATHER GG; KUNZE KL; HARR JE; LEPAGE F; LEVY RH
    PREDICTION OF POTENTIAL-DRUG INTERACTIONS USING CYP450 INHIBITION SPECTRA FOR D2916 AND D3187
    Epilepsia
    
    G.G. Mather et al., "PREDICTION OF POTENTIAL-DRUG INTERACTIONS USING CYP450 INHIBITION SPECTRA FOR D2916 AND D3187", Epilepsia, 36, 1995, pp. 253-253
42. LEPAGE F; GILLARDIN JM; TOMBRET F; GIRARD P; DESCOMBE JJ; TANG C; MATHER GG; LEVY RH; BAILLIE TA
    HUMAN AND RAT-METABOLISM OF D2916 AND ANTICONVULSANT PROPERTIES OF ITS METABOLITES
    Epilepsia
    
    F. Lepage et al., "HUMAN AND RAT-METABOLISM OF D2916 AND ANTICONVULSANT PROPERTIES OF ITS METABOLITES", Epilepsia, 36, 1995, pp. 261-261
43. STEPHENS JR; MATHER GG; LEVY RH
    VALPROATE (VPA) INTERACTION WITH ENDOTOXIN AND TNF
    Epilepsia
    
    J.R. Stephens et al., "VALPROATE (VPA) INTERACTION WITH ENDOTOXIN AND TNF", Epilepsia, 36, 1995, pp. 265-265
44. MATHER GG; BISHOP FE; TRAGER WF; KUNZE KK; THUMMEL KE; SHEN DD; ROSKOS LK; LEPAGE F; GILLARDIN JM; LEVY RH
    MECHANISMS OF STIRIPENTOL INTERACTIONS WITH CARBAMAZEPINE AND PHENYTOIN
    Epilepsia
    
    G.G. Mather et al., "MECHANISMS OF STIRIPENTOL INTERACTIONS WITH CARBAMAZEPINE AND PHENYTOIN", Epilepsia, 36, 1995, pp. 162-163
45. VERLEYE M; HEULARD I; STEPHENS JR; LEVY RH; GILLARDIN JM
    EFFECTS OF CITRULLINE MALATE ON BACTERIAL LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA IN RATS
    Arzneimittel-Forschung
    
    M. Verleye et al., "EFFECTS OF CITRULLINE MALATE ON BACTERIAL LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA IN RATS", Arzneimittel-Forschung, 45-1(6), 1995, pp. 712-715
46. ARENDS RHGP; ZHANG KY; LEVY RH; BAILLIE TA; SHEN DD
    STEREOSELECTIVE PHARMACOKINETICS OF STIRIPENTOL - AN EXPLANATION FOR THE DEVELOPMENT OF TOLERANCE TO ANTICONVULSANT EFFECT
    Epilepsy research
    
    R.H.G.P. Arends et al., "STEREOSELECTIVE PHARMACOKINETICS OF STIRIPENTOL - AN EXPLANATION FOR THE DEVELOPMENT OF TOLERANCE TO ANTICONVULSANT EFFECT", Epilepsy research, 18(2), 1994, pp. 91-96
47. ZHANG KY; TANG CY; RASHED M; CUI DH; TOMBRET F; BOTTE H; LEPAGE F; LEVY RH; BAILLIE TA
    METABOLIC CHIRAL INVERSION OF STIRIPENTOL IN THE RAT .1. MECHANISTIC STUDIES
    Drug metabolism and disposition
    
    K.Y. Zhang et al., "METABOLIC CHIRAL INVERSION OF STIRIPENTOL IN THE RAT .1. MECHANISTIC STUDIES", Drug metabolism and disposition, 22(4), 1994, pp. 544-553
48. TANG CY; ZHANG KY; LEPAGE F; LEVY RH; BAILLIE TA
    METABOLIC CHIRAL INVERSION OF STIRIPENTOL IN THE RAT .2. INFLUENCE OFROUTE OF ADMINISTRATION
    Drug metabolism and disposition
    
    C.Y. Tang et al., "METABOLIC CHIRAL INVERSION OF STIRIPENTOL IN THE RAT .2. INFLUENCE OFROUTE OF ADMINISTRATION", Drug metabolism and disposition, 22(4), 1994, pp. 554-560
49. ANDERSON GD; ACHEAMPONG AA; LEVY RH
    INTERACTION BETWEEN VALPROATE AND BRANCHED-CHAIN AMINO-ACID-METABOLISM
    Neurology
    
    G.D. Anderson et al., "INTERACTION BETWEEN VALPROATE AND BRANCHED-CHAIN AMINO-ACID-METABOLISM", Neurology, 44(4), 1994, pp. 742-744
50. FINNELL RH; KERR BM; VANWAES M; STEWARD RL; LEVY RH
    PROTECTION FROM PHENYTOIN-INDUCED CONGENITAL-MALFORMATIONS BY COADMINISTRATION OF THE ANTIEPILEPTIC DRUG STIRIPENTOL IN A MOUSE MODEL
    Epilepsia
    
    R.H. Finnell et al., "PROTECTION FROM PHENYTOIN-INDUCED CONGENITAL-MALFORMATIONS BY COADMINISTRATION OF THE ANTIEPILEPTIC DRUG STIRIPENTOL IN A MOUSE MODEL", Epilepsia, 35(1), 1994, pp. 141-148
51. STEPHENS JR; LEVY RH
    EFFECTS OF VALPROATE AND CITRULLINE ON AMMONIUM-INDUCED ENCEPHALOPATHY
    Epilepsia
    
    J.R. Stephens e R.H. Levy, "EFFECTS OF VALPROATE AND CITRULLINE ON AMMONIUM-INDUCED ENCEPHALOPATHY", Epilepsia, 35(1), 1994, pp. 164-171
52. KERR BM; THUMMEL KE; WURDEN CJ; KLEIN SM; KROETZ DL; GONZALEZ FJ; LEVY RH
    HUMAN LIVER CARBAMAZEPINE METABOLISM - ROLE OF CYP3A4 AND CYP2C8 IN 10,11-EPOXIDE FORMATION
    Biochemical pharmacology
    
    B.M. Kerr et al., "HUMAN LIVER CARBAMAZEPINE METABOLISM - ROLE OF CYP3A4 AND CYP2C8 IN 10,11-EPOXIDE FORMATION", Biochemical pharmacology, 47(11), 1994, pp. 1969-1979
53. FINNELL RH; VANWAES M; MUSSELMAN A; KERR BM; LEVY RH
    DIFFERENCES IN THE PATTERNS OF PHENYTOIN-INDUCED MALFORMATIONS FOLLOWING STIRIPENTOL COADMINISTRATION IN 3 INBRED MOUSE STRAINS
    Reproductive toxicology
    
    R.H. Finnell et al., "DIFFERENCES IN THE PATTERNS OF PHENYTOIN-INDUCED MALFORMATIONS FOLLOWING STIRIPENTOL COADMINISTRATION IN 3 INBRED MOUSE STRAINS", Reproductive toxicology, 7(5), 1993, pp. 439-448
54. KLEIN SM; ELMER GW; MCFARLAND LV; SURAWICZ CM; LEVY RH
    RECOVERY AND ELIMINATION OF THE BIOTHERAPEUTIC AGENT, SACCHAROMYCES-BOULARDII, IN HEALTHY-HUMAN VOLUNTEERS
    Pharmaceutical research
    
    S.M. Klein et al., "RECOVERY AND ELIMINATION OF THE BIOTHERAPEUTIC AGENT, SACCHAROMYCES-BOULARDII, IN HEALTHY-HUMAN VOLUNTEERS", Pharmaceutical research, 10(11), 1993, pp. 1615-1619
55. PISANI F; HAJYEHIA A; FAZIO A; ARTESI C; OTERI G; PERUCCA E; KROETZ DL; LEVY RH; BIALER M
    CARBAMAZEPINE VALNOCTAMIDE INTERACTION IN EPILEPTIC PATIENTS - IN-VITRO IN-VIVO CORRELATION
    Epilepsia
    
    F. Pisani et al., "CARBAMAZEPINE VALNOCTAMIDE INTERACTION IN EPILEPTIC PATIENTS - IN-VITRO IN-VIVO CORRELATION", Epilepsia, 34(5), 1993, pp. 954-959
56. KROETZ DL; LOISEAU P; GUYOT M; LEVY RH
    IN-VIVO AND IN-VITRO CORRELATION OF MICROSOMAL EPOXIDE HYDROLASE INHIBITION BY PROGABIDE
    Clinical pharmacology and therapeutics
    
    D.L. Kroetz et al., "IN-VIVO AND IN-VITRO CORRELATION OF MICROSOMAL EPOXIDE HYDROLASE INHIBITION BY PROGABIDE", Clinical pharmacology and therapeutics, 54(5), 1993, pp. 485-497